Moleculin Biotech Long Term Debt

Moleculin Biotech (MBRX) currently reports a long-term debt of $190K as of March 2026. That compares with $330K in the prior-year period — down 43.3% year over year. Use the charts on this page to explore Moleculin Biotech's long-term debt history and peer comparisons.

Moleculin Biotech's long-term debt decreased from $330K to $190K — a 43.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Moleculin Biotech reported $190K in long-term debt as of March 2026. That compares with $330K in the prior-year period — down 43.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $190K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Moleculin Biotech, and consider following MBRX for alerts when major investors trade the stock.

Moleculin Biotech is classified in the Healthcare sector. On long-term debt, it currently shows $190K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBRX with unrelated industries.